Device Trial Radar · NCT03503877
Media, Morphokinetics, and Mosaicism
Last checked: Nov 19, 2026Latest source record: Dec 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
Feb 14, 2018
Primary completion
Nov 28, 2019
Study completion Nov 28, 2019
Sponsor
- Lead sponsor
- University of California, San FranciscoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 20, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Female only, from 18 years, up to 42 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Embryonic aneuploidy is the underlying etiology for the majority of failed implantation and miscarriage. Preimplantation genetic screening (PGS) with transfer of a euploid embryo has been advocated as a strategy for increasing live birth rates with a single embryo transfer. Culturing embryos to the blastocyst stage for trophectoderm biopsy is a requirement for PGS. Several commercially-available single-step embryonic culture media with varying composition have been established for use in the IVF laboratory. Early reports have suggested differences in clinical outcomes, such as aneuploidy and miscarriage rates, with distinct culture media currently in standard use. However, there have been no clinical trials demonstrating the superiority of any one commercially-available culture media formulation. As a result, clinics use media with varying composition based upon familiarity and cost.
Conditions
- Embryonic Mosaicism
- Embryo Culture Media
- Embryo Morphokinetics
- Infertility
Interventions
EmbryoScope PlusDevice
All embryos will be cultured in the EmbryoScope Plus to obtain morphokinetic data
GLOBAL MEDIAOther
Embryos will be cultured in GLOBAL media
SAGE MEDIAOther
Embryos will be cultured in SAGE media
Primary outcomes
What the sponsor says the trial is designed to measure.
- Aneuploidy RatesTime frame: Preimplantation Genetic Testing at blastocyst stage of embryo development, 2 weeks from start of IVF treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.